Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow
Compose a Response to This Article
Other responses
No responses have been published for this article.
